NORTHVALE, N.J., July 8, 2008 (PRIME NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (AMEX:ELI), a specialty pharmaceutical company focused primarily on developing and commercializing proprietary abuse resistant, extended release pain management products, filed its annual report on Form 10-K for the fiscal year ended March 31, 2008 (the "Form 10-K") with the Securities and Exchange Commission. The Company's revenues for the fiscal year ended March 31, 2008 were $1,413,119, an increase of $269,278 or approximately 24% over revenues for the prior year. The revenue increase was primarily due to the first full year of revenues from Lodrane 24D(r), the Company's second commercial product, which was launched in the later part of the fiscal year ended March 31, 2007.
